Verrica Pharmaceuticals (VRCA) Projected to Post Quarterly Earnings on Tuesday

Verrica Pharmaceuticals (NASDAQ:VRCA) is expected to be announcing its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.59) per share and revenue of $4.5140 million for the quarter. Investors are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:30 PM ET.

Verrica Pharmaceuticals (NASDAQ:VRCA) last issued its earnings results on Wednesday, March 11th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.08). The business had revenue of $5.09 million for the quarter, compared to the consensus estimate of $4.52 million. On average, analysts expect Verrica Pharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Verrica Pharmaceuticals Stock Up 8.6%

Verrica Pharmaceuticals stock traded up $0.55 during midday trading on Tuesday, hitting $6.91. 24,288 shares of the company’s stock were exchanged, compared to its average volume of 124,469. Verrica Pharmaceuticals has a 12 month low of $3.28 and a 12 month high of $9.82. The company has a market cap of $118.64 million, a PE ratio of -4.37 and a beta of 1.54. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.45 and a current ratio of 2.59. The firm has a 50-day moving average of $5.72 and a two-hundred day moving average of $6.13.

Analyst Ratings Changes

A number of analysts have recently weighed in on VRCA shares. Zacks Research cut shares of Verrica Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Tuesday, April 7th. TD Cowen restated a “buy” rating on shares of Verrica Pharmaceuticals in a report on Wednesday, January 7th. Finally, Wall Street Zen cut shares of Verrica Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Verrica Pharmaceuticals has an average rating of “Reduce” and an average target price of $17.00.

Hedge Funds Weigh In On Verrica Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the stock. XTX Topco Ltd purchased a new position in shares of Verrica Pharmaceuticals in the 4th quarter valued at approximately $122,000. Quadrature Capital Ltd purchased a new position in shares of Verrica Pharmaceuticals in the 4th quarter valued at approximately $99,000. Man Group plc purchased a new position in shares of Verrica Pharmaceuticals in the 4th quarter valued at approximately $94,000. Squarepoint Ops LLC purchased a new position in shares of Verrica Pharmaceuticals in the 4th quarter valued at approximately $276,000. Finally, OMERS ADMINISTRATION Corp purchased a new position in shares of Verrica Pharmaceuticals in the 4th quarter valued at approximately $188,000. 42.45% of the stock is owned by hedge funds and other institutional investors.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica’s approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off‐label use of existing treatments.

Beyond VP-102, Verrica is advancing VP-103, a next‐generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions.